Anti-CD134 / OX40L receptor antibody (ab203220)
Key features and details
- Rabbit polyclonal to CD134 / OX40L receptor
- Suitable for: IHC-P, WB
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Overview
-
Product name
Anti-CD134 / OX40L receptor antibody
See all CD134 / OX40L receptor primary antibodies -
Description
Rabbit polyclonal to CD134 / OX40L receptor -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, WBmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide within Human CD134/ OX40L receptor aa 100-200 conjugated to keyhole limpet haemocyanin. The exact immunogen sequence used to generate this antibody is proprietary information. If additional detail on the immunogen is needed to determine the suitability of the antibody for your needs, please contact our Scientific Support team to discuss your requirements.
Database link: P43489 -
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Proclin 300
Constituents: 50% Glycerol (glycerin, glycerine), 1% BSA, 48.98% TBS, 1X
Aqueous buffered solution -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab203220 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P | (3) |
1/100 - 1/500.
1/50-1/200 when using fluorescent detection methods. |
WB |
Use at an assay dependent concentration.
|
Notes |
---|
IHC-P
1/100 - 1/500. 1/50-1/200 when using fluorescent detection methods. |
WB
Use at an assay dependent concentration. |
Target
-
Function
Receptor for TNFSF4/OX40L/GP34. -
Sequence similarities
Contains 4 TNFR-Cys repeats. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 7293 Human
- Entrez Gene: 22163 Mouse
- Entrez Gene: 25572 Rat
- Omim: 600315 Human
- SwissProt: P43489 Human
- SwissProt: P47741 Mouse
- SwissProt: P15725 Rat
- Unigene: 129780 Human
see all -
Alternative names
- ACT 35 antibody
- ACT35 antibody
- ACT35 antigen antibody
see all
Images
-
Formaldehyde-fixed, paraffin-embedded mouse spleen tissue stained for CD134 / OX40L receptor using ab203220 at 1/200 dilution in immunohistochemical analysis.
-
Formaldehyde-fixed, paraffin-embedded mouse spleen tissue stained for CD134 / OX40L receptor using ab203220 at 1/200 dilution in immunohistochemical analysis.
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab203220 has been referenced in 4 publications.
- Guo H et al. An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC). Oncoimmunology 10:1947665 (2021). PubMed: 34290908
- Miyahara H et al. Unique cell tropism of HHV-6B in an infantile autopsy case of primary HHV-6B encephalitis. Neuropathology N/A:N/A (2018). PubMed: 29582466
- Liu T et al. Immunomodulatory effects of OX40Ig gene-modified adipose tissue-derived mesenchymal stem cells on rat kidney transplantation. Int J Mol Med 39:144-152 (2017). WB ; Rat . PubMed: 27878248
- Wang J et al. PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. Cancer Prev Res (Phila) 10:684-693 (2017). PubMed: 29018057